Purpose of review Microvascular ischemic disease of the brain is a common cause of cognitive impairment and dementia, particularly in the context of preexisting cardiovascular risk factors and aging. This review summarizes our current understanding of the emerging molecular themes that underlie progressive and irreparable vascular disease leading to neuronal tissue injury and dementia.
INTRODUCTION
Dementia is characterized by progressive decline in cognitive ability leading to impaired autonomy of function. Dementia has become a serious public health problem given its profound impact to individuals, families, and society at large. This problem is significantly amplified by an increasingly aging population, and the soaring prevalence of cardiometabolic risk factors. Thus, a clear mechanistic understanding of predisposing conditions, biomarkers for prognosis, and molecular drivers of dementia has become of paramount importance.
Neuronal dysfunction and degeneration, such as the one resulting from the accumulation of bamyloid protein associated with Alzheimer's disease constitute the major cause for dementia, accounting for 60-70% of the cases. Nonetheless, the realization that vascular disease alone or in conjunction with other causes of neurodegeneration contributes substantially to dementia has expanded an interest in understanding vascular brain health [1] .
Vascular dementia is the second most common form of dementia. Unfortunately, it is generally underrecognized and poorly understood [1] . Much like Alzheimer's disease, vascular disease in the brain impairs higher cortical processes including reasoning, planning, and memory as reduced cerebral blood flow leads to secondary focal neuronal injury with irreversible tissue loss. Although it has been estimated that vascular cause of dementia constitutes up to 20% of cases in the elderly, the inconspicuous nature of the symptoms and the common coexistence of vascular disease with other neurodegenerative processes, would suggest that the true contribution of vascular mechanisms to dementia is likely to be significantly higher [2, 3] .
In the clinic, MRI of the brain provides detailed in-vivo imaging of the progressive changes associated with neurological disorders, cognitive decline and dementia. This technology shows brain volume loss as the ultimate outcome of seemingly different pathophysiological processes (Fig. 1a-d ). Till date, MRI remains the most effective form for diagnosis and noninvasive tool to assess disease progression, but it does not identify causation and it is unable to pinpoint molecular mechanisms for the disease.
Microvascular ischemic disease of the brain contributing to dementia most commonly represents a complex disorder that emerges over decades from the convergence of multiple factors disrupting vessel physiology and integrity ultimately resulting in neuronal injury. Highly penetrant monogenic forms of microvascular ischemic disease of the brain leading to vascular dementia have been recently identified. These disorders constitute important models to understand the sensitive relationship between vascular and neuronal health.
Here, we examine the recent developments on our understanding of the genetic and predisposing risk factors associated with vascular dementia with a focus on molecular mechanisms.
Monogenic causes of vascular dementia
Although most of the literature stresses the contribution of cardiometabolic risk factors and age as key determinants of vascular dementia, several monogenic diseases lead to a phenotype of early-onset cerebrovascular disease. These findings strongly argue for the key role of genetics as a potential independent cause for the condition.
Monogenic causes that could lead to vascular dementia include mutations in NOTCH3 (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, CADASIL), HTRA1 (cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy, CARASIL), COL4A1/COL4A2 (small vessel arteriopathy and cerebral hemorrhage), TREX1 (cerebro-retinal vasculopathy) and GLA (Fabry disease) ( Table 1) .
The most common form of monogenic hereditary vasculopathy associated with dementia is CADASIL [4 & ]. Patients with this disease often become symptomatic in the second to fourth decade of life with complex migraine phenomena and strokes. Because of the brain MRI appearance ( Fig. 1) and their relative young age, patients with CADASIL are often misdiagnosed as suffering multiple sclerosis.
CADASIL is associated with progressive degeneration of vascular smooth muscle cells in small and medium-size arteries. The cellular and molecular alterations affect vascular contractility, impair barrier function and promote vascular fragility [5] [6] [7] . Despite the fact that these changes are systemic in nature, the disorder is clinically manifested in the brain leading, over several decades, to multifocal ischemia with progressive impairment of cognitive function [8] .
CADASIL is caused from mutations in the NOTCH3 gene [9] which codes for a receptor with predominant expression in arterial smooth muscle cells. NOTCH3 regulates multiple aspects of vascular homeostasis, including tone, vascular tension, and endothelial health [10] . This receptor is a complex protein with a large extracellular domain containing multiple endothelial growth factor-like repeats and a small transmembrane and intracellular portion. CADASIL disease-causing mutations occur in the extracellular domain of the receptor. Although the genetic cause of CADASIL has been known for 20 years, understanding how NOTCH3 dysfunction leads to the disease is still limited. This is partially because of the wide genetic diversity of mutations and the incomplete understanding of NOTCH3 function in blood vessels. In this issue, Ferrante and colleagues specifically focus on the clinical and cellular aspects of the disease (Ferrante et al. [11] ).
A second monogenic cerebrovascular disease similar to CADASIL in symptoms and in MRI presentation has been recently identified and linked to HTRA1 (HtrA serine peptidase 1). The disease was named CARASIL [12, 13] . HTRA1 codes for a serine protease with broad target specificity. Some of its
KEY POINTS
Cerebrovascular alterations have been recently recognized as significant causes of dementia, only second to Alzheimer's disease.
Several monogenic and polygenic causes for vascular dementia target genes that regulate smooth muscle cell contractility, association of vascular cells with the extracellular matrix, and response to growth factors.
In addition to hereditary conditions, systemic burden associated with diabetes and hypertension is strong contributing factors in cerebrovascular disease.
At the molecular level, several of these risk factors produce an imbalance between production and removal of ROS by antioxidant species that has been linked to the pathogenesis of dementia.
substrates include extracellular matrix proteins, proteoglycans, and growth factor-binding proteins. Through its ability to target proteoglycans, HRTA1 controls the release of fibroblast growth factor and it also regulates the availability of insulin-like growth factors, as per its ability to cleave insulin-like growth factor-binding proteins. As CADASIL, CARASIL affects vascular smooth muscle cells and it is systemic in nature, but symptoms are more severely manifested in the brain likely because of this organ's sensitivity to changes in oxygen levels. Precise information as to the molecular consequences of HTRA1 mutations in smooth muscle cells remains unclear. Recently, heterozygous mutations in the HTRA1 gene have been also associated with microvascular disease of the brain in older individuals, suggesting high sensitivity to protein levels [14] . Emerging molecular mechanisms of vascular dementia Romay et al.
As an abundant component of basement membranes, type IV collagen is critical in maintaining vascular integrity. Thus, it is not surprising that mutations in the COL4A1 and A2 genes has been linked to small vessel arteriopathy and cerebral hemorrhages [15] . Just like the two previous syndromes, this arteriopathy is systemic; however, the brain's low tolerance for microhemorrhages makes this organ more sensitive to pathologies which result in significant leukoencephalopathy and dementia.
Mutations in TREX1 have been associated with retinal vasculopathy and cerebral leukodystrophy [21] . Symptoms for this disorder start in adulthood and frequently include rapid loss of vision, multifocal strokes, and dementia. The mechanisms involved in this disease are unclear, as it is the role of TREX1 in vascular homeostasis. Interestingly, TREX1 codes for an exonuclease that degrades double-stranded DNA. It has been proposed that degradation of double-stranded DNA by TREX1 prevent this polynucleotide from acting as an autoantigen to inappropriately activate the immune system. Mutations in TREX1 are also is responsible for several interferon-mediated autoinflammatory diseases including chilblain lupus and Aicardi-Goutières syndrome type-1.
Absent or markedly reduced activity of the agalactosidase enzyme (GLA gene) results in Fabry disease, an X-linked lysosomal storage disorder. This disorder is characterized by the accumulation of globotriaosylceramide and related glycosphingolipids in plasma and lysosomes of blood vessels, nerves, and other organs [16] . This abnormal accumulation of glycosphingolipids yields cerebrovascular disease and neuropathy in addition to renal failure, cardiac disease, and skin manifestations [17] . Stroke or transient ischemic attacks occur in about 11% of the patients and these subsequently lead to vascular dementia [18] .
Polymorphisms and vascular dementia
Apart from the monogenic causes of vascular dementia discussed above, multiple risk-alleles associated with microvascular ischemic disease of the brain have been recently identified. Here, we highlight polymorphisms in genes expressed by vascular cells and that were found in at least two independent studies.
The structural integrity of the vascular endothelium relies on junctional proteins. Brain vessels, in particular, express high levels of claudins which contribute to form the blood-brain barrier. Claudins play an important role in organizing tight junctions between endothelial cells. Polymorphisms of CLDN1 (claudin1) were recently associated with small vessel vascular dementia [19] . Further supporting a previous study indicating that claudin expression profile alone was able to segregate Alzheimer's disease cases from normal aging and from vascular dementia patients [20] . Given their critical role to promote vascular integrity, it is likely that more polymorphisms and/ or mutations in structural junctional proteins will continue to emerge as genetic risk factors.
Perhaps not surprising, some variants associated with systemic vascular disease were also associated with cerebrovascular disease. One of the risk-alleles identified by genome wise association studies (GWAS) for vascular dementia was apolipoprotein E, which codes for a protein involved in lipid metabolism. This association has been reported by several studies including one with more than 10 000 study participants [22, 23] . Another, lipid-related gene, PON1 (paraoxonase 1) was also associated with a higher risk of vascular dementia [24] . Paraoxonase 1 is an enzyme with lactonase and ester hydrolase activity which in the circulation binds to high-density lipoprotein and is responsible for the hydrolysis of xenobiotics. Polymorphisms in this gene also cause atherosclerosis and diabetic retinopathy. In addition, polymorphisms in regulatory proteins associated with inflammation, such as tumor necrosis factor alpha [25] and transforming growth factor beta1 [26] were also found to be highly correlated with vascular dementia.
Although not exclusively associated with vascular brain disease, polymorphisms in several other genes have been identified by GWAS. Figure 2 highlights genes that were independently identified in at ]. Of note, HDAC9 was associated with large artery atherosclerosis stroke and ALDH2 with small artery stroke.
As for genetic modifiers, limited clinical reports have identified concurrent mutations in CADASIL patients that may contribute to early disease progression. These include: factor V Leiden and methylene tretrahydrofolate reductase (MTHFR) [34] .
Brain ischemic and hemorrhagic events: a path to vascular dementia
According to many epidemiological studies, dementia occurs in one-third of stroke victims and a previous stroke doubles the risk of dementia compared to age and sex-matched controls. During the first-year poststroke, there is a nine-fold excess risk of dementia that only gets reduced to four-fold risk thereafter [35] . In fact, a major long-term consequence of stroke is cognitive and functional deficit and incidence of stroke impairs cognitive function regardless of race or ethnicity [36] .
Strokes emerge as localized, focal events at the level of the microcirculation because of underlying genetic, cardiometabolic and/or other predisposing factors [37 & ] (Fig. 2) . Embolic strokes have the implication of a proximal source of embolism (often the heart chambers of valves, or large extra or intracranial vessels) that release clot fragments to more distant branches of the vascular network lodging in smaller portions of the vascular tree with ensuing ischemia. Strokes could also emerge from disruptions of the vascular wall. Often, injury to the vascular tissue results in extravasation of blood components which under some circumstances, such as uncontrolled hypertension, might evolve into life-threatening intracranial hematomas.
Risk factors associated with stroke and dementia
Adverse cardiometabolic profiles have been associated with cerebrovascular alterations. In some cases, these factors predispose to what is called silent infarcts, which lack stroke-like symptoms, but are found by neuroimaging or upon necropsy. These silent infarcts promote subclinical changes that are thought to progressively underlie vascular dementia as well as cognitive and functional decline. Although functional decline can be viewed as consequence of aging, systemic burden associated particularly with diabetes and hypertension clearly accelerates deficits. These factors promote constant and irreparable 'wearing' of the cerebral vasculature, a premature form of vascular aging. Below we discuss the key risk factors identified with vascular dementia and their underlying molecular mechanisms.
Diabetes -several epidemiological studies have associated prevalence of diabetes with stroke, particularly small artery disease (lacunar stroke), stroke recurrence, and stroke mortality [38] . In fact, glycemic index from nearly 3000 patients was independently associated with impaired endothelial function and severity of the stroke [39 & ] . At the molecular level, alterations in circulating glucose affect levels of reactive oxygen species (ROS) that promote oxidative stress [40 & ]. Although low levels of ROS can be beneficial to cellular physiology, high and constant ROS can impair mitochondrial function, promote hypoxia, and even cell death [41] . Imbalance in ROS has been directly associated with the pathogenesis of dementia [42] . Specifically, patients with vascular dementia have high levels of plasma lipid peroxidation [43] , reduced plasma antioxidant levels [44] , and increased DNA oxidation in their cerebrospinal fluid [45] . Although one could claim that the findings are correlative, as measurements of ROS are indirect and obtained from the circulation, evidence that ROS is an important underlying mechanism has been further supported by direct inihibition of nidotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX). NOX is the major source of ROS in endothelial cells [46] and its inhibition attenuated chronic cerebral hypoperfusion in mouse models [47] .
Hypertension -hypertension emerges as the largest contributor to the overall societal burden of stroke. Approximately 40% of first-time strokes in their 50s and 60s are attributable to hypertension [48] . Furthermore, recent meta-analysis studies demonstrated that adherence to antihypertensive medications strongly reduced stroke risk in hypertensive patients [49 & ]. Here once again, ROS might be an important molecular mechanism. Angiotensin II (AngII) is a critical mediator of hypertension and it has been shown to promote vascular disease through several mechanisms that also converge on the increase ROS levels resulting in endothelial damage and dysfunction [50, 51] . Molecularly, AngII directly stimulates NOX1 and NOX2 in vascular cells [52, 53] . Furthermore, it is well accepted that AngII regulation of NOX1 and NOX2 affect hypertrophy in smooth muscle cells [54, 55] , and therefore, it is critical to vascular contractility (and hypertension).
Hypercholesterolemia -although familial, hypercholesterolemia did not confer an increased risk of ischemic stroke [56 & ]; more than half of stroke patients had elevated cholesterol levels and variants in proprotein convertase subtilisin/Kexin type 9 (PCSK9) that reduce cholesterol were found to be protective against ischemic stroke [57 & ]. These two recent studies seem to be at odds with one another, clearly more investigations are necessary. Importantly, at the molecular level, and similar to diabetes, hypercholesterolemia can also lead to increase in ROS contributing to vascular wall wearing [58] .
A common underlying mechanism of the most important risk factors in stroke and vascular dementia appears to be ROS and NOX. Further supporting this concept, inactivation of NOX2 in mice completely eliminates the functional hyperemia and pathological changes in cerebral blood vessels [59, 60] . Moreover, a pharmacological inhibitor of NOX oxidase blocked generation of ROS and prevented cerebrovascular dysfunction caused by AngII [61, 62] . Clearly, experimental evidence is strong and progression to the clinic, particularly in relation to hypertension patients should be a priority.
CONCLUSION
Significant contributors to morbidity and disability in aging populations are cerebrovascular disease associated with dementia. Although vascular abnormalities are intimately linked with progressive deterioration in the health status of the brain, large fractions of the underlying pathogenesis and molecular mechanisms are unknown. Robust data on epidemiologic, genetic, and causal associations are progressively uncovering genetic predispositions, but generation of specific animal models and preclinical studies are critical to further validate the findings.
Research focus would benefit from combinatorial studies which take into account already identified cardiometabolic factors with genetic risks. Major obstacles relate to the heterogeneity of the disease, its slow progression, and the challenge of integrating vascular microenvironment with genetics. A clear understanding of the molecular wiring of brain endothelial and smooth muscle cells and their unique transcriptional makeup will expand our ability to identify factors that might be of more specific relevance to the brain. Through the rapid advances in single-cell RNA transcriptomics this is rapidly becoming a reality [63 && ]. Such information will expand our ability to systematically integrate risk factors and genetics using more clear outcomes and molecular readouts.
